Synthesis and Biological and Structural Characterization of the Dual-Acting Peroxisome Proliferator-Activated Receptor α/γ Agonist Ragaglitazar

Journal of Medicinal Chemistry
2003.0

Abstract

A new and improved synthesis of the peroxisome proliferator-activated receptor (PPAR) agonist ragaglitazar applicable for large-scale preparation has been developed. The convergent synthetic procedure was based on a novel enzymatic kinetic resolution step. The conformation of ragaglitazar bound to the hPPARgamma receptor was quite different compared to the single-crystal structures of the l-arginine salt of ragaglitazar. In particular, the phenoxazine ring system had varying orientations. Ragaglitazar had high affinity for the hPPARalpha and -gamma receptors with IC(50) values of 0.98 and 0.092 microM, respectively. The lack of hPPARdelta activity could be explained by the absence of binding in the tail-up pocket in the hPPARdelta receptor, in contrast to the hPPARdelta agonist GW2433, which was able to bind in both the tail-up and tail-down pockets of the receptor.

Knowledge Graph

Similar Paper

Synthesis and Biological and Structural Characterization of the Dual-Acting Peroxisome Proliferator-Activated Receptor α/γ Agonist Ragaglitazar
Journal of Medicinal Chemistry 2003.0
Design and Synthesis of Dual Peroxisome Proliferator-Activated Receptors γ and δ Agonists as Novel Euglycemic Agents with a Reduced Weight Gain Profile
Journal of Medicinal Chemistry 2006.0
Design and Structural Analysis of Novel Pharmacophores for Potent and Selective Peroxisome Proliferator-activated Receptor γ Agonists
Journal of Medicinal Chemistry 2009.0
Design and Synthesis of α-Aryloxyphenylacetic Acid Derivatives:  A Novel Class of PPARα/γ Dual Agonists with Potent Antihyperglycemic and Lipid Modulating Activity
Journal of Medicinal Chemistry 2005.0
Design, Synthesis, and Structural Analysis of Phenylpropanoic Acid-Type PPARγ-Selective Agonists: Discovery of Reversed Stereochemistry−Activity Relationship
Journal of Medicinal Chemistry 2011.0
Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes
Bioorganic & Medicinal Chemistry Letters 2009.0
Synthesis and evaluation of a series of benzopyran derivatives as PPAR α/γ agonists
European Journal of Medicinal Chemistry 2008.0
Insights into the Mechanism of Partial Agonism
Journal of Biological Chemistry 2007.0
Design, synthesis, and structure–activity relationship of carbamate-tethered aryl propanoic acids as novel PPARα/γ dual agonists
Bioorganic & Medicinal Chemistry Letters 2007.0
Structure-activity relationships of rosiglitazone for peroxisome proliferator-activated receptor gamma transrepression
Bioorganic & Medicinal Chemistry Letters 2017.0